Relay Therapeutics
General Information | |
Business: |
We are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Our company is built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. These insights may enable us to more effectively drug protein targets that previously have been intractable (i.e. inadequately drugged or undruggable). |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 122 |
Founded: | 2015 |
Contact Information | |
Address | 399 Binney Street, 2nd Floor, Cambridge, MA 02139, US |
Phone Number | (617) 370-8837 |
Web Address | http://www.relaytx.com |
View Prospectus: | Relay Therapeutics |
Financial Information | |
Market Cap | $1737.5mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-86.0 mil (last 12 months) |
IPO Profile | |
Symbol | RLAY |
Exchange | NASDAQ |
Shares (millions): | 20.0 |
Price range | $20.00 - $20.00 |
Est. $ Volume | $400.0 mil |
Manager / Joint Managers | J.P. Morgan/ Goldman Sachs/ Cowen and Company/ Guggenheim Securities |
CO-Managers | - |
Expected To Trade: | 7/16/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |